Phase 4 Rheumatoid Arthritis Trial, Recruiting NCT02714634 Sponsor: University Hospital, Strasbourg, France Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Phase 4 Rheumatoid Arthritis Trial, Recruiting

NCT02714634
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with rheumatoid arthritis (RA) based on recognised international medical guidelines (EULAR/ACR 2010 criteria)
  • People whose RA is considered moderately to highly active, based on a standard disease activity score (DAS28-CRP above 3.2)
  • People whose RA has not responded well enough to the medicine methotrexate (taken weekly at 15mg or more for at least 3 months), or to leflunomide (taken daily for at least 3 months)
  • People who have joint damage visible on X-ray and/or specific blood markers associated with RA (rheumatoid factor and/or anti-CCP antibodies)
  • People aged 18 years or older
  • People who have read, understood, and signed a written consent form before any trial procedures begin
  • People who are enrolled in a social insurance system
  • Women who could potentially become pregnant must have a negative pregnancy test (β-HCG) before joining
  • Women who could potentially become pregnant must agree to use an effective method of contraception throughout the trial and for a period after it ends (the required duration depends on which medicine is used — confirm with trial site)

Who may not be able to join:

  • People who have previously been treated with, or who have a medical reason preventing the use of, targeted therapies such as biologics or JAK/STAT inhibitors
  • People who have previously received "triple therapy" (a combination of three specific RA medicines — confirm with trial site)
  • People who have another type of inflammatory joint condition in addition to RA, except for RA combined with Sjögren's syndrome
  • People who have medical reasons preventing the use of all biologics, JAK/STAT inhibitors, or all of the following medicines: methotrexate, leflunomide, sulfasalazine, and hydroxychloroquine
  • People who have been taking corticosteroids (such as prednisone) at a dose higher than 15mg per day for at least 4 weeks before joining the trial
  • People who have not been screened for tuberculosis
  • People who would not be able to attend follow-up appointments over 12 months
  • People who are pregnant, breastfeeding, or planning to become pregnant within the next 12 months
  • People with a current dependency on drugs or alcohol
  • People who have taken part in another clinical trial involving an investigational medicine within the 4 weeks before this trial's treatment begins
  • Women who could potentially become pregnant and are not using an effective form of contraception
  • People who are under legal protection orders (confirm with trial site)
  • People who are currently imprisoned

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: 3 88 12 79 53

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
30 March 2016
Est. completion
1 March 2029

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Numbers of participant with low disease activity (DAS28-CRP<3.2) and a daily dose ≤ 7.5 mg/day of equivalent prednisone

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov